IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v8y2017i1d10.1038_ncomms14687.html
   My bibliography  Save this article

RETRACTED ARTICLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

Author

Listed:
  • Richard Hill

    (University of Algarve
    Centre for Biomedical Research (CBMR), University of Algarve
    Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth)

  • Patricia A. Madureira

    (Centre for Biomedical Research (CBMR), University of Algarve)

  • Bibiana Ferreira

    (Centre for Biomedical Research (CBMR), University of Algarve)

  • Inês Baptista

    (Centre for Biomedical Research (CBMR), University of Algarve)

  • Susana Machado

    (Centre for Biomedical Research (CBMR), University of Algarve)

  • Laura Colaço

    (Centre for Biomedical Research (CBMR), University of Algarve)

  • Marta dos Santos

    (Centre for Biomedical Research (CBMR), University of Algarve)

  • Ningshu Liu

    (Bayer AG, Drug Discovery Oncology Research)

  • Ana Dopazo

    (Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC))

  • Selma Ugurel

    (University Hospital Essen)

  • Angyal Adrienn

    (University of Sheffield)

  • Endre Kiss-Toth

    (University of Sheffield)

  • Murat Isbilen

    (Bilkent University)

  • Ali O. Gure

    (Bilkent University)

  • Wolfgang Link

    (University of Algarve
    Centre for Biomedical Research (CBMR), University of Algarve
    Algarve Biomedical Center (ABC), University of Algarve)

Abstract

Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. Here we report that tribbles homologue 2 (TRIB2) ablates forkhead box O activation and disrupts the p53/MDM2 regulatory axis, conferring resistance to various chemotherapeutics. TRIB2 suppression is exerted via direct interaction with AKT a key signalling protein in cell proliferation, survival and metabolism pathways. Ectopic or intrinsic high expression of TRIB2 induces drug resistance by promoting phospho-AKT (at Ser473) via its COP1 domain. TRIB2 expression is significantly increased in tumour tissues from patients correlating with an increased phosphorylation of AKT, FOXO3a, MDM2 and an impaired therapeutic response. This culminates in an extremely poor clinical outcome. Our study reveals a novel regulatory mechanism underlying drug resistance and suggests that TRIB2 functions as a regulatory component of the PI3K network, activating AKT in cancer cells.

Suggested Citation

  • Richard Hill & Patricia A. Madureira & Bibiana Ferreira & Inês Baptista & Susana Machado & Laura Colaço & Marta dos Santos & Ningshu Liu & Ana Dopazo & Selma Ugurel & Angyal Adrienn & Endre Kiss-Toth , 2017. "RETRACTED ARTICLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT," Nature Communications, Nature, vol. 8(1), pages 1-9, April.
    • Handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14687
    DOI: 10.1038/ncomms14687
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms14687
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms14687?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14687. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.